UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Update on Hsp90 inhibitors in clinical trial

Current topics in medicinal chemistry, 2009-11, Vol.9 (15), p.1479-1492

2009

Volltextzugriff (PDF)

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer

International journal of cancer, 2016-10, Vol.139 (7), p.1648-1657

2016

Volltextzugriff (PDF)

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer

Annals of oncology, 2016-04, Vol.27 (4), p.693-699

2016

Volltextzugriff (PDF)

A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

Annals of oncology, 2018-10, Vol.29, p.viii334-viii334

2018

Volltextzugriff (PDF)

Caspase-dependent deubiquitination of monoubiquitinated nucleosomal histone H2A induced by diverse apoptogenic stimuli

Cell death and differentiation, 2001-12, Vol.8 (12), p.1182-1196

2001

Volltextzugriff (PDF)

A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion

Oncogene, 2008-04, Vol.27 (17), p.2478-2487

2008

Volltextzugriff (PDF)

Impact of Extracellular Folate Levels on Global Gene Expression

Molecular pharmacology, 2001-12, Vol.60 (6), p.1288-1295

2001

Volltextzugriff (PDF)

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

Leukemia, 2001-10, Vol.15 (10), p.1537-1543

2001

Volltextzugriff (PDF)

Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy

Current molecular medicine, 2012-11, Vol.12 (9), p.1125-1141

2012

Volltextzugriff (PDF)

DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells

British journal of cancer, 2003-02, Vol.88 (4), p.599-605

2003

Volltextzugriff (PDF)

FLT3 regulates β-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells

Leukemia, 2007-12, Vol.21 (12), p.2476-2484

2007

Volltextzugriff (PDF)

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition

British journal of cancer, 2007-09, Vol.97 (6), p.741-744

2007

Volltextzugriff (PDF)

Five‐lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions

The FASEB journal, 2001-09, Vol.15 (11), p.2007-2009

2001

Volltextzugriff (PDF)

Development of flow cytometric predictive biomarker assay for response to PARP inhibitor (PARPi) therapy in high-grade serous ovarian cancer (HGSOC)

Gynecologic oncology, 2014-06, Vol.133, p.104-104

2014

Volltextzugriff (PDF)

Distinct immune characteristics in women with deleterious germline BRCA1/2 mutations (gBRCAm)-associated high-grade serous ovarian cancer (HGSOC)

Gynecologic oncology, 2015-04, Vol.137, p.44-44

2015

Volltextzugriff (PDF)

A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib

United European gastroenterology journal, 2015-10, Vol.3 (5), p.453-461

2015

Volltextzugriff (PDF)

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer

Clinical cancer research, 1996-03, Vol.2 (3), p.483-491

1996

Volltextzugriff (PDF)

Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway

Molecular and Cellular Biology, 1996-10, Vol.16 (10), p.5839-5845

1996

Volltextzugriff (PDF)

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

Haematologica (Roma), 2014-06, Vol.99 (6), p.e81-e83

2014

Volltextzugriff (PDF)

Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling

Oncogene, 2001-10, Vol.20 (46), p.6718-6723

2001

Volltextzugriff (PDF)

Regulation of BRCA1 by protein degradation

Oncogene, 1999-11, Vol.18 (47), p.6460-6468

1999

Volltextzugriff (PDF)

Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3

Cancer research (Chicago, Ill.), 1995-05, Vol.55 (10), p.2122-2128

1995

Volltextzugriff (PDF)

HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability

Cancer cell, 2005-08, Vol.8 (2), p.143-153

2005

Volltextzugriff (PDF)

MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor β type II receptor expression in human breast cancer cells

Cancer research (Chicago, Ill.), 2001-02, Vol.61 (3), p.931-934

2001

Volltextzugriff (PDF)

Terminal Neuroendocrine Differentiation of Human Prostate Carcinoma Cells in Response to Increased Intracellular Cyclic AMP

Proceedings of the National Academy of Sciences - PNAS, 1994-06, Vol.91 (12), p.5330-5334

1994

Volltextzugriff (PDF)

1 – 25 von 327

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(309)
Mit Volltextzugriff
(284)

Publikationsform

Sprache

Englisch
(313)
Japanisch
(47)
Deutsch
(16)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(198)
Life Sciences & Biomedicine
(185)
Humans
(179)
Oncology
(83)
Biological And Medical Sciences
(79)
Animals
(74)
Male
(69)
Female
(54)
Medical Sciences
(52)
Tumor Cells, Cultured
(48)
Biochemistry & Molecular Biology
(46)
Mice
(41)
Cell Biology
(39)
Middle Aged
(39)
Aged
(36)
Tumors
(34)
Adult
(31)
Fundamental And Applied Biological Sciences. Psychology
(31)
Cell Line
(30)
Pharmacology. Drug Treatments
(30)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Update on Hsp90 inhibitors in clinical trial

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer

A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

Caspase-dependent deubiquitination of monoubiquitinated nucleosomal histone H2A induced by diverse apoptogenic stimuli

A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion

Impact of Extracellular Folate Levels on Global Gene Expression

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy

DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells

FLT3 regulates β-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition

Five‐lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions

Development of flow cytometric predictive biomarker assay for response to PARP inhibitor (PARPi) therapy in high-grade serous ovarian cancer (HGSOC)

Distinct immune characteristics in women with deleterious germline BRCA1/2 mutations (gBRCAm)-associated high-grade serous ovarian cancer (HGSOC)

A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib

Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer

Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling

Regulation of BRCA1 by protein degradation

Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3

HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability

MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor β type II receptor expression in human breast cancer cells

Terminal Neuroendocrine Differentiation of Human Prostate Carcinoma Cells in Response to Increased Intracellular Cyclic AMP

Suchergebnisse filtern